E
Elias Jabbour
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1303
Citations - 29725
Elias Jabbour is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 71, co-authored 1108 publications receiving 21641 citations. Previous affiliations of Elias Jabbour include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Sequential Combination of Low-Intensity Chemotherapy (Mini-hyper-CVD) Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Phase 2 Trial
Koji Sasaki,Hagop M. Kantarjian,Farhad Ravandi,Nicholas J. Short,Partow Kebriaei,Xuelin Huang,Michael Rytting,Nitin Jain,Marina Konopleva,Guillermo Garcia-Manero,Richard E. Champlin,Tapan M. Kadia,Jorge E. Cortes,Zeev Estrov,Koichi Takahashi,Morgan Mace,Maria Khouri,Patrice Nasnas,Jovitta Jacob,Rebecca E. Garris,Elias Jabbour +20 more
TL;DR: The sequential addition of blinatumomab to mini-hyper-CVD + inotuzumab ozogamicin might further improve survival and minimize the risk of veno-occlusive disease (VOD) by allowing a reduction of inotizumab dose and spacing allogeneic stem cell transplant (ASCT) from the last dose of inotinumab.
Journal ArticleDOI
Interim Analysis of Phase II Study of Venetoclax with 10-Day Decitabine (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome
Abhishek Maiti,Courtney D. DiNardo,Jorge E. Cortes,Gautam Borthakur,Naveen Pemmaraju,Christopher B. Benton,Tapan M. Kadia,Koichi Takahashi,Kiran Naqvi,Farhad Ravandi,Yesid Alvarado,Nicholas J. Short,Naval Daver,Koji Sasaki,Maro Ohanian,Guillermo Garcia-Manero,Philip A. Thompson,Steven M. Kornblau,Lucia Masarova,Nitin Jain,Elias Jabbour,Michael Andreeff,Rita Maduike,Julio A Guerrero,Qi Zhang,Antonio Cavazos,Helen Ma,Caitlin R. Rausch,Carol Bivins,Kenneth Vaughan,Sherry Pierce,Jing Ning,Wei Qiao,John S. Welch,Hagop M. Kantarjian,Marina Konopleva +35 more
TL;DR: A phase II trial to evaluate the safety and efficacy of VEN with 10-days (D) of decitabine (DEC) in AML and high risk MDS and to determine overall response rate (ORR) including complete remission (CR), CR with incomplete blood count recovery (CRi), partial remission (PR), and morphologic leukemia-free state in pts with AML.
Journal ArticleDOI
Novel therapies for relapsed acute lymphoblastic leukemia.
TL;DR: The addition of targeted therapy in Philadelphia chromo some-positive ALL has improved responses in relapsed patients without resistance to available tyrosine kinase inhibitors.
Journal ArticleDOI
A Phase II Study of the Hyper-CVAD Regimen in Sequential Combination with Blinatumomab As Frontline Therapy for Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Guillaume Richard-Carpentier,Hagop M. Kantarjian,Nicholas J. Short,Farhad Ravandi,Alessandra Ferrajoli,Heather M Schroeder,Maria Khouri,Guillermo Garcia-Manero,Guillermo Montalban Bravo,Jorge E. Cortes,Nitin Jain,Marina Konopleva,Koichi Takahashi,Koji Sasaki,Rebecca E. Garris,Elias Jabbour +15 more
TL;DR: The primary outcome was relapse-free survival (RFS) and secondary outcomes were overall survival (OS), overall response rate and MRD negativity rate.
Journal ArticleDOI
Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemia
TL;DR: The role of monoclonal antibodies in adult ALL is reviewed and the current and future approaches in ALL are summarized, including novel combination therapies and the possibility of early incorporation of these agents into treatment regimens.